Epicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedLoading investors…
Activity from announced rounds
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
Developing best-in-class radiopharmaceuticals for cancer treatment
Pitching Duquesne Family Office? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room